English

Akoya Biosciences, Inc.

EDGAR

AKYA Quarterly report (10-Q) · filed 2025-05-13

Annual consolidated revenue for 2024: about Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 81.67M, using the latest reported figures. The previous period, 2023, was about Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 96.63M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

16.6 million Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

2025 Q1 · Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

Exact inputs and evidence

Revenue: 16639000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source

Operating margin

-80.61%

2025 Q1 · %

Exact inputs and evidence

Operating Income: -13412000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source
Revenue: 16639000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source

Operating cash flow

-7.21 million Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

2025 Q1 · Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

Exact inputs and evidence

Operating Cash Flow: -7214000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source

Free cash flow

-7.42 million Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

2025 Q1 · Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ

Exact inputs and evidence

Operating Cash Flow: -7214000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source
Capital Expenditure: 204000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ Source

Cash and cash equivalents: 20.4 million Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ 2025-03-31 Source
Exact value

20357000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ
Long-term debt including current maturities: 76.5 million Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ 2025-03-31 Source
Exact value

76487000 Unit_Standard_USD_aLB9yImDuUS7L5OosDkPrQ
Shares outstanding: 49.8 million Unit_Standard_shares_O3WWqQXOzUKN_CbXvCQo7A 2025-03-31 Source
Exact value

49836931 Unit_Standard_shares_O3WWqQXOzUKN_CbXvCQo7A

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-13.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2024-12-31
Operating income: 2 of 11 periods available· newest 2024-12-31
Net income: 2 of 11 periods available· newest 2024-12-31
Operating cash flow: 2 of 11 periods available· newest 2024-12-31
Capital expenditure: 2 of 11 periods available· newest 2024-12-31
Total assets: Multiple units; comparison withheld· newest 2024-12-31
Total liabilities: Multiple units; comparison withheld· newest 2024-12-31
Current assets: Multiple units; comparison withheld· newest 2024-12-31
Current liabilities: Multiple units; comparison withheld· newest 2024-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2024-12-31
Long-term debt including current maturities: Multiple units; comparison withheld· newest 2024-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-15.5%

Prior period

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 96.63 million

2023-01-01 – 2023-12-31
Current period

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 81.67 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

81672000 − 96633000 = -14961000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA

96633000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
81672000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Year-over-year change in Revenue: -14961000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 81672000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2545406 Filing: 000155837025003124 Input fundies:Revenue: 96633000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2546438 Filing: 000155837025003124
The citation records this snapshot. The page link may show a newer release later.
Net income
+Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 7.96 million

Prior period

−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 63.32 million

2023-01-01 – 2023-12-31
Current period

−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 55.37 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-55365000 − -63323000 = 7958000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA

-63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Year-over-year change in Net income: 7958000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2460010 Filing: 000155837025003124 Input fundies:NetIncome: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2461008 Filing: 000155837025003124
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 6.8 million

Prior period

−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 50.9 million

2023-01-01 – 2023-12-31
Current period

−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 44.1 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-44103000 − -50899000 = 6796000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA

-50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Year-over-year change in Operating cash flow: 6796000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1573047 Filing: 000155837025003124 Input fundies:OperatingCashFlow: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1508297 Filing: 000155837025003124
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-32.8%

Prior period

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 3.65 million

2023-01-01 – 2023-12-31
Current period

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2.46 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

2456000 − 3653000 = -1197000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA

3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Year-over-year change in Capital expenditure: -1197000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1511177 Filing: 000155837025003124 Input fundies:CapitalExpenditure: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1512192 Filing: 000155837025003124
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 81.67 million 100% of revenue
Cost of revenue Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 33.79 million 41% of revenue
Operating expenses Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 94.61 million 116% of revenue
Operating income −Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 46.73 million −57% of revenue
Tax, interest and other Derived Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 8.64 million 11% of revenue
Net income −Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 55.37 million −68% of revenue

Cash

Operating cash flow −Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 44.1 million −54% of revenue
Capital expenditure Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2.46 million 3% of revenue
Free cash flow Derived −Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 46.56 million −57% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 160% of revenue.
2024 Operating loss: operating costs were 157% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	96633000	154301000 Derived	-57668000	5655000 Derived	-63323000	-54552000 Derived	Source 2023-01-01 – 2023-12-31: 96633000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Revenue Open source 2023-01-01 – 2023-12-31: -57668000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Net Income Open source 2023-01-01 – 2023-12-31: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	81672000	128402000 Derived	-46730000	8635000 Derived	-55365000	-46559000 Derived	Source 2024-01-01 – 2024-12-31: 81672000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Revenue Open source 2024-01-01 – 2024-12-31: -46730000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Net Income Open source 2024-01-01 – 2024-12-31: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 81.7M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA)	Source evidence
20232023-12-31	Revenue	96633000	Revenue: 96633000 Open source
20242024-12-31	Revenue	81672000	Revenue: 81672000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-15.5% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 96633000 Open source
20242024-12-31	Year over year	-15.5%	Revenue: 81672000 Open source Revenue: 96633000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -57.2% 2024

Net margin -67.8% 2024

Free cash flow margin -57% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-59.7%	Operating Income: -57668000 Open source Revenue: 96633000 Open source
20242024-12-31	Operating margin	-57.2%	Operating Income: -46730000 Open source Revenue: 81672000 Open source
20232023-12-31	Net margin	-65.5%	Net Income: -63323000 Open source Revenue: 96633000 Open source
20242024-12-31	Net margin	-67.8%	Net Income: -55365000 Open source Revenue: 81672000 Open source
20232023-12-31	Free cash flow margin	-56.5%	Revenue: 96633000 Open source Operating Cash Flow: -50899000 Open source Capital Expenditure: 3653000 Open source
20242024-12-31	Free cash flow margin	-57%	Revenue: 81672000 Open source Operating Cash Flow: -44103000 Open source Capital Expenditure: 2456000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA -44.1M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA)	Source evidence
20232023-12-31	Operating cash flow	-50899000	Operating Cash Flow: -50899000 Open source
20242024-12-31	Operating cash flow	-44103000	Operating Cash Flow: -44103000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA -46.6M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA)	Source evidence
20232023-12-31	Free cash flow	-54552000	Operating Cash Flow: -50899000 Open source Capital Expenditure: 3653000 Open source
20242024-12-31	Free cash flow	-46559000	Operating Cash Flow: -44103000 Open source Capital Expenditure: 2456000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 63.32 million Exact value Exact value: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2023-01-01 – 2023-12-31: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Net Income Open source Share or cite Citation for Net Income · Akoya Biosciences, Inc. · 2023-12-31 Akoya Biosciences, Inc. (edgar:1711933) Net Income: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:NetIncome: -63323000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2461008 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 50.9 million Exact value Exact value: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2023-01-01 – 2023-12-31: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akoya Biosciences, Inc. · 2023-12-31 Akoya Biosciences, Inc. (edgar:1711933) Operating Cash Flow: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:OperatingCashFlow: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1508297 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 3.65 million Exact value Exact value: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2023-01-01 – 2023-12-31: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akoya Biosciences, Inc. · 2023-12-31 Akoya Biosciences, Inc. (edgar:1711933) Capital Expenditure: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:CapitalExpenditure: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1512192 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 54.55 million Calculation and evidence -50899000 − 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Exact free cash flow: -54552000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2023-01-01 – 2023-12-31: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akoya Biosciences, Inc. · 2023-12-31 Akoya Biosciences, Inc. (edgar:1711933) Free cash flow: -54552000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50899000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1508297 Filing: 000155837025003124 Input fundies:CapitalExpenditure: 3653000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1512192 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 55.37 million Exact value Exact value: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2024-01-01 – 2024-12-31: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Net Income Open source Share or cite Citation for Net Income · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Net Income: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:NetIncome: -55365000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#2460010 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 44.1 million Exact value Exact value: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2024-01-01 – 2024-12-31: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Operating Cash Flow: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:OperatingCashFlow: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1573047 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2.46 million Exact value Exact value: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2024-01-01 – 2024-12-31: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Capital Expenditure: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA&dimensions= Input fundies:CapitalExpenditure: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1511177 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 46.56 million Calculation and evidence -44103000 − 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Exact free cash flow: -46559000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA 2024-01-01 – 2024-12-31: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Akoya Biosciences, Inc. · 2024-12-31 Akoya Biosciences, Inc. (edgar:1711933) Free cash flow: -46559000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1711933?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44103000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1573047 Filing: 000155837025003124 Input fundies:CapitalExpenditure: 2456000 Unit_Standard_USD_mWCCmer0LUGAq1cbdYBTXA (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1711933/000155837025003124/akya-20241231x10k.htm#1511177 Filing: 000155837025003124 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

20 filings · 2,712 latest values · 2,712 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001711933, 1711933, AKYA, edgar:1711933

Also known as Akoya Biosciences, Inc., Akoya Biosciences, Inc.

Akoya Biosciences, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation